The Turkish NSCLC market
will grow at a rate of 7% per year between 2012 and 2017, and the number of
NSCLC incident cases will grow by nearly 30% between 2012 and 2022. Changing
medical practice, growing NSCLC population, and persistent use of branded
agents offer significant opportunity to multinational companies (MNCs) with
emerging therapies in this indication. In this report, we examine the trends
within Turkey’s NSCLC pharmaceutical market, which is characterized by the growing
use of targeted therapies, changes in reimbursement policy, the
introduction of several new agents, and the Turkish government’s stringent
Primary research: 73 oncologists surveyed across Turkey. Separate in-depth interviews with 8 Turkish oncologists.
Epidemiology: Total incident cases of NSCLC in Turkey over a ten-year period (2012-2022) by age, stage, gender, and histology.
Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Turkey.
Pricing and reimbursement: Prices of NSCLC therapies in Turkey versus other major markets and analysis of the impact of government reimbursement on treatment trends.
Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, antitubulins, antimetabolites, other cytotoxic agents, EGFR inhibitors, angiogenesis inhibitors, ALK inhibitors, immunotherapies, and c-Met inhibitors from 2012 through 2017, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.